Newsroom

[The New York Times] $1,000 Hepatitis Pill Shows Why Fixing Health Costs Is So Hard

A new drug for the liver disease hepatitis C is scaring people. Not because the drug is dangerous — it’s generally heralded as a genuine medical breakthrough — but […]

Read more

Gilead Can Afford to Take These Three Steps to Lower the Price of Sovaldi

Yesterday’s blockbuster earnings announcement from Gilead underscores how much room the drug manufacturer has to lower the price of its Hepatitis C drug Sovaldi.  In fact, […]

Read more

[NCHC] Earnings Report Shows Gilead Can Lower Sovaldi’s Unsustainable Price

Statement from the National Coalition on Health Care’s President and CEO John Rother on the latest quarterly earnings report from Gilead Sciences, Inc., manufacturer of the […]

Read more

[SFGate] Gilead hepatitis C pill reaches $3.48 billion in quarterly sales

“The fundamental concern is Sovaldi and other speciality drugs are going to put an unsustainable burden on the health insurance system,” said John Rother, CEO of […]

Read more